Use of trastuzumab emtansine (T-DM1; K) after pertuzumab plus trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW)

被引：0
|
作者：
Sanglier, T. [1 ]
Fabi, A. [2 ]
Flores, C. [3 ]
Flahavan, E. [4 ]
Lindegger, N. [5 ]
Montemurro, F. [6 ]
机构：
[1] F Hoffmann La Roche Ltd, RWD Oncol, Basel, Switzerland
[2] Ist Nazl Tumori Regina Elena, Oncol Med, Rome, Italy
[3] Genentech Inc, RWD Oncol, San Francisco, CA 94080 USA
[4] F Hoffmann La Roche Ltd, RWD Oncol, Welwyn Garden City, Herts, England
[5] F Hoffmann La Roche Ltd, Med Affairs Oncol, Global Prod Dev, Basel, Switzerland
[6] Candiolo Canc Inst, Day Hosp Oncol Multidisciplinare, Candiolo, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
356P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Tyrosine kinase inhibitors (TKIs) in HER2-positive metastatic breast cancer after trastuzumab emtansine (T-DM1) failure: A multicenter real-world study
    Sun, C.
    Yin, Y.
    Li, W.
    Huang, X.
    Hua, Y.
    Jin, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S368 - S369
  • [42] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Emi Noguchi
    Kenji Tamura
    Masaya Hattori
    Jun Horiguchi
    Nobuaki Sato
    Kazumitsu Kanatani
    Kiyoshi Matsunaga
    Hiroji Iwata
    Yasuhiro Fujiwara
    Breast Cancer, 2019, 26 : 39 - 46
  • [43] Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer
    Baez-Vallecillo, L.
    Raghavendra, A. Singareeka
    Hess, K.
    Moulder, S. L.
    Tripathy, D.
    Valero, V.
    Murthy, R. K.
    CANCER RESEARCH, 2017, 77
  • [44] A phase lb study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+breast cancer (MBC).
    Waks, Adrienne Gropper
    Keenan, Tanya
    Li, Tianyu
    Tayob, Nabihah
    Wulf, Gerburg M.
    Richardson, Edward T.
    Mittendorf, Elizabeth A.
    Overmoyer, Beth
    Krop, Ian E.
    Winer, Eric P.
    Van Allen, Eliezer Mendel
    Agudo, Judith
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
    Martin, M.
    Fumoleau, P.
    Dewar, J. A.
    Albanell, J.
    Limentani, S. A.
    Campone, M.
    Chang, J. C.
    Patre, M.
    Strasak, A.
    de Haas, S. L.
    Xu, J.
    Garcia-Saenz, J. A.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1249 - 1256
  • [46] Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
    Neelima Denduluri
    Janet L. Espirito
    Michelle D. Hackshaw
    Chuck Wentworth
    Tamy Recchia
    Winghan J. Kwong
    Drugs - Real World Outcomes, 2023, 10 : 177 - 186
  • [47] Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
    Denduluri, Neelima
    Espirito, Janet L.
    Hackshaw, Michelle D.
    Wentworth, Chuck
    Recchia, Tamy
    Kwong, Winghan J.
    DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 177 - 186
  • [48] YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
    Fujihara, Miwa
    Shien, Tadahiko
    Shien, Kazuhiko
    Suzawa, Ken
    Takeda, Tatsuaki
    Zhu, Yidan
    Mamori, Tomoka
    Otani, Yusuke
    Yoshioka, Ryo
    Uno, Maya
    Suzuki, Yoko
    Abe, Yuko
    Hatono, Minami
    Tsukioki, Takahiro
    Takahashi, Yuko
    Kochi, Mariko
    Iwamoto, Takayuki
    Taira, Naruto
    Doihara, Hiroyoshi
    Toyooka, Shinichi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [49] The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
    Peipei Liu
    Jiajun Fan
    Ziyu Wang
    Wenjing Zai
    Ping Song
    Yongping Li
    Dianwen Ju
    AMB Express, 10
  • [50] Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
    Sawaki, Masataka
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 37 - 41
12345